[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR2134292A1 - Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine - Google Patents

Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine

Info

Publication number
FR2134292A1
FR2134292A1 FR7115591A FR7115591A FR2134292A1 FR 2134292 A1 FR2134292 A1 FR 2134292A1 FR 7115591 A FR7115591 A FR 7115591A FR 7115591 A FR7115591 A FR 7115591A FR 2134292 A1 FR2134292 A1 FR 2134292A1
Authority
FR
France
Prior art keywords
interferon
rifampycine
rifamycine
days
desoxyuridines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7115591A
Other languages
French (fr)
Other versions
FR2134292B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to FR7115591A priority Critical patent/FR2134292A1/en
Publication of FR2134292A1 publication Critical patent/FR2134292A1/en
Application granted granted Critical
Publication of FR2134292B1 publication Critical patent/FR2134292B1/fr
Granted legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The use of a combination of interferon with a halodesoxuridine, rifamycine or rifampycine or their derivs., gives a greater antiviral effect than interferon alone. In an example, a patient suffering from a herpes infection of the cornea was treated with iodo-desoxyuridine and, after 5 days, with interferon followed by more iodo-desoxyridine. After three days an ulcer on the cornea had reduced in size by 2/3, and after 10 days was completely closed. The last application of interferon was made after 12 days.
FR7115591A 1971-04-30 1971-04-30 Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine Granted FR2134292A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7115591A FR2134292A1 (en) 1971-04-30 1971-04-30 Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7115591A FR2134292A1 (en) 1971-04-30 1971-04-30 Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine

Publications (2)

Publication Number Publication Date
FR2134292A1 true FR2134292A1 (en) 1972-12-08
FR2134292B1 FR2134292B1 (en) 1976-05-14

Family

ID=9076232

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7115591A Granted FR2134292A1 (en) 1971-04-30 1971-04-30 Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine

Country Status (1)

Country Link
FR (1) FR2134292A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001102A1 (en) * 1979-10-19 1981-04-30 A Romano Medicine for the treatment of viral infections of the eye and other organs
EP0080032A2 (en) * 1981-11-20 1983-06-01 Enzo Biochem, Inc. Pharmaceutical preparation for treating herpetic lesions
EP0109234A1 (en) * 1982-11-04 1984-05-23 Syntex (U.S.A.) Inc. Compositions comprising interferon and their therapeutic use
EP0199451A2 (en) * 1985-03-16 1986-10-29 The Wellcome Foundation Limited Therapeutic nucleosides
WO2000057187A2 (en) * 1999-03-19 2000-09-28 Vanderbilt University Diagnosis and treatment of multiple sclerosis
US6258532B1 (en) 1997-08-14 2001-07-10 Vanderbilt University Methods for in vitro susceptibility testing of chlamydia
US6710033B1 (en) 1996-08-14 2004-03-23 Vanderbilt University Methods and treatment of multiple sclerosis
US6890526B2 (en) 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001102A1 (en) * 1979-10-19 1981-04-30 A Romano Medicine for the treatment of viral infections of the eye and other organs
EP0080032A2 (en) * 1981-11-20 1983-06-01 Enzo Biochem, Inc. Pharmaceutical preparation for treating herpetic lesions
EP0080032A3 (en) * 1981-11-20 1985-11-13 Enzo Biochem, Inc. Pharmaceutical preparation for treating herpetic lesions
EP0109234A1 (en) * 1982-11-04 1984-05-23 Syntex (U.S.A.) Inc. Compositions comprising interferon and their therapeutic use
EP0199451A2 (en) * 1985-03-16 1986-10-29 The Wellcome Foundation Limited Therapeutic nucleosides
EP0199451B1 (en) * 1985-03-16 1996-03-06 The Wellcome Foundation Limited Therapeutic nucleosides
US6710033B1 (en) 1996-08-14 2004-03-23 Vanderbilt University Methods and treatment of multiple sclerosis
US6890526B2 (en) 1997-05-06 2005-05-10 Vanderbilt University Methods and reagents for the treatment of multiple sclerosis
US6258532B1 (en) 1997-08-14 2001-07-10 Vanderbilt University Methods for in vitro susceptibility testing of chlamydia
US7094397B2 (en) 1997-08-14 2006-08-22 Vanderbilt Unversity Methods and reagents for the treatment of multiple sclerosis
WO2000057187A2 (en) * 1999-03-19 2000-09-28 Vanderbilt University Diagnosis and treatment of multiple sclerosis
WO2000057187A3 (en) * 1999-03-19 2001-04-19 Univ Vanderbilt Diagnosis and treatment of multiple sclerosis

Also Published As

Publication number Publication date
FR2134292B1 (en) 1976-05-14

Similar Documents

Publication Publication Date Title
SE7502341L (en)
FR2134292A1 (en) Interferon compsns - contg halo desoxyuridines rifamycine or rifampycine
CA931666A (en) Patient treatment table
CA975903A (en) Sperm oil substitute and its use in leather treatment
IL35811A0 (en) O,s-dialkyl-o'-cyanophenyl-phosphorothiolates,their preparation and their use for controlling microorganisms
IL40933A0 (en) Phenylformamidines,their manufacture and their use in pest control
GB1230455A (en)
Restifo The comparative morphology of the penis in the Libellulid genera Celithemis, Leucorrhinia, and Libellula (Odonata)
BARKHATOVA et al. Treating the secretions of a human with the aid of a naturally forming algal-bacterial colony(Biological procession of human secretions and water regeneration by Chlorella in bacterial colony)
CA969175A (en) 6.alpha.,9.alpha.-DIFLUOROSTEROIDS OF THE PREGNANE SERIES AND PROCESSES FOR THEIR MANUFACTURE
CA641909A (en) 12.alpha.-ALKYL-17.alpha.,21-DIHYDROXY-1,4-PREGNADIENE-3,11,20-TRIONE AND 9.alpha.-HALO DERIVATIVES THEREOF
CA646287A (en) 3-oxo-.delta.1,4 and .delta.1,4,6-steroids using 2,3-cyano-1,4-benzoquinones
AU277472B2 (en) Improvements in or relating tothe manufacture of nonfibrous, hydrophilic films
AU2477262A (en) Improvements in or relating tothe manufacture of nonfibrous, hydrophilic films
AU260396B2 (en) Improvements in the processing of high cis-1,4 butadiene-1,3 polymers
AU1413162A (en) Improvements in the processing of high cis-1,4 butadiene-1,3 polymers
AU451403B2 (en) 'substituted1-(3',5-dihydroxyphenyl)-2-cycoalkyl amino butanol derivatives effectice in the treatment of bronchospastic conditions"
AU273555B2 (en) Improvements in and relating tothe treatment of leather
CA618314A (en) 1,1,2-trifluoroethylfluorosulfonate and fumigation process
AU274771B2 (en) Improvements in or relating to 3, 4-benzoaporphine and derivatives thereof
CA643967A (en) 9.alpha.-CHLORO- AND 9.alpha.-BROMO-11-OXO-5.alpha.-STEROIDS AND THEIR PREPARATION
CA866782A (en) 16.alpha.-METHYL-9,11-OXIDO-17.alpha.,21-DIHYDROXY-1,4-PREGNADIENE-3,20-DIONE AND METHOD OF PREPARING THE SAME
CA621153A (en) 3,3-disubstituted-2-azetidinones and manufacture thereof
AU1298670A (en) 'substituted1-(3',5-dihydroxyphenyl)-2-cycoalkyl amino butanol derivatives effectice in the treatment of bronchospastic conditions"
AU3382763A (en) Improvements in and relating tothe treatment of leather

Legal Events

Date Code Title Description
ST Notification of lapse